Ashwagandha supplementation enhances ovarian tumoricidal activity of NK cells

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Ovarian cancer (OVCA) is a fatal malignancy of women with highest case to death ratio among gynecological cancers. OVCA differs from other malignancies that it mainly disseminates locally in the peritoneal and abdominal cavity. Thus, factors in tumor microenvironment play critical roles in tumor progression as well as prevention of OVCA metastasis. Innate immune cells are members of tumor microenvironment and first responders to a developing tumor. However, tumor suppresses anti-tumor immune responses by secreting immunosuppressive factors, which in most cases, shift anti-tumor functions of innate immune cells to pro-tumor roles favoring tumor growth. Natural killer (NK) cells are a member of innate immunity with cytotoxic functions necessary to eliminate a growing tumor. However, our preliminary studies showed that progression of ovarian tumors to late stages was associated with the inhibition of NK cell infiltration to the tumor vicinity. Our preliminary studis further showed that this tumor-induced inhibition of intra-tumor NK cell infiltration was mediated by shedding of major histocompatibility complex class I related chain A (MICA) expressed on the surface of malignant cells. MICA is a ligand of NK cell receptor NKG2D. Upon binding with MICA, NKG2D activates NK cells for cytotoxic activities. Shedding of MICA by the tumor from its surface prevents NK cells to recognize the tumor cells, thus, the tumor escapes cytotoxic effects of NK cells. Dietary supplementation of hens (with or without OVCA) with Ashwagandha root powder in our preliminary study showed inhibition of tumor progression and reduced incidence of new OVCA cases. Ashwagandha is an herb used in traditional medicine as anti-stressor and inflammatory agent. Proposed study seeks to confirm these preliminary observations in a large cohort of hens by two Specific Aims. Aim 1 will determine the efficacy of Ashwagandha in increasing the influx of intra-tumoral NK cells and thus enhancing ovarian tumoricidal role of NK cells. Aim 2 will determine the length of exposure to dietary Ashwagandha supplementation required to maintain a long- term anti-tumor activities of NK cells. Successful accomplishment of the proposed study will generate noble information and will be helpful for a longer study and/or an early phase clinical study to examine the role of Ashwagandha in enhancing ovarian tumoricidal functions of NK cells.